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Abstract
An emerging cellular immunotherapy for cancer is based on the cytolytic activity of natural
killer (NK) cells against a wide range of tumors. Although in vitro activation, or “priming,” of
NK cells by exposure to pro-inflammatory cytokines, such as interleukin (IL)-2, has been
extensively studied, the biological consequences of NK cell activation in response to target
cell interactions have not been thoroughly characterized. We investigated the conse-
quences of co-incubation with K562, CTV-1, Daudi RPMI-8226, and MCF-7 tumor cell lines
on the phenotype, cytokine expression profile, and transcriptome of human NK cells. We
observe the downregulation of several activation receptors including CD16, CD62L, C-X-C
chemokine receptor (CXCR)-4, natural killer group 2 member D (NKG2D), DNAX accessory
molecule (DNAM)-1, and NKp46 following tumor-priming. Although this NK cell phenotype
is typically associated with NK cell dysfunction in cancer, we reveal the upregulation of NK
cell activation markers, such as CD69 and CD25; secretion of pro-inflammatory cytokines,
including macrophage inflammatory proteins (MIP-1) α /β and IL-1β/6/8; and overexpres-
sion of numerous genes associated with enhanced NK cell cytotoxicity and immunomodula-
tory functions, such as FAS, TNFSF10, MAPK11, TNF, and IFNG. Thus, it appears that
tumor-mediated ligation of receptors on NK cells may induce a primed state which may or
may not lead to full triggering of the lytic or cytokine secreting machinery. Key signaling mol-
ecules exclusively affected by tumor-priming include MAP2K3, MARCKSL1, STAT5A, and
TNFAIP3, which are specifically associated with NK cell cytotoxicity against tumor targets.
Collectively, these findings help define the phenotypic and transcriptional signature of NK
cells following their encounters with tumor cells, independent of cytokine stimulation, and
provide insight into tumor-specific NK cell responses to inform the transition toward harness-
ing the therapeutic potential of NK cells in cancer.
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Introduction
Natural killer (NK) cell responses are influenced by signals from numerous germline-encoded
receptors on the cell surface. NK cell-mediated cytotoxicity against target tumor cells requires
the co-engagement of several activation receptors—such as the natural cytotoxicity receptors
(NCRs) NKp46 and NKp80—or other co-stimulatory receptors—including natural killer
group 2 member D (NKG2D) or DNAX accessory molecule (DNAM)-1 [1]. Once activated,
NK cells exhibit cytotoxicity against a variety of neoplastic cells and produce a wide array of
immunoregulatory cytokines, such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α
[2]. Activated NK cells can also secrete chemokines that aid in initiating inflammatory
responses and recruiting other immune cells to inflammatory sites, including macrophage
inflammatory proteins (MIP)-1α/β, IL-8, and RANTES (resting and normal T cell expressed
and secreted).
In vitro activation of NK cells can be achieved via target cell recognition and/or exposure to
one or more pro-inflammatory cytokines. Pre-incubating NK cells with IL-2 results in the gen-
eration of a lymphokine-activated killer (LAK) cell, whereas pre-incubating with target tumor
cells generates a “tumor-primed” NK cell (TpNK) [3, 4]. In both cases, the “primed” state can
be defined by an NK cell’s ability to kill target cells that previously exhibited little to no sensi-
tivity to resting NK cells. Although cytokines that share a common cytokine-receptor gamma
chain (or CD132) such as IL-2 and IL-15 exhibit some redundant signaling, they also have spe-
cific functions in regulating NK cell responses [5]. The gamma-chain receptor associates with
the Janus tyrosine-kinase (JAK)-3 to phosphorylate different downstream signal transducer
and activator of transcription (STAT) molecules depending on the type of receptors engaged.
Exposure to these cytokines alone or in combination with others, such as IL-12 or IL-18, can
induce different and, in some cases synergistic, effects on NK cell effector functions. This
cooperation can also be achieved via non-redundant ligand combinations in target cells.
Human NK cell responses to exogenous cytokines have been extensively studied; however,
relatively little is known about the biological and functional consequences of NK cell priming
following interaction with target cells. Previous studies on the activation profile of cytokine-
stimulated NK cells have revealed that NK cells upregulate receptors and key molecules
involved in the cell cycle, cell proliferation, and immune responses [6]. Although different
effects have been reported depending on the cytokines used, the majority of altered NK cell
transcripts are involved in cytokine/chemokine signaling. In contrast, studies characterizing
the tumor-associated NK cell profile using NK cells isolated from cancer patients have
reported downregulation of NK cell activation receptors, and genes involved in cytokine sig-
naling [7, 8]. Although the downregulation of NK cell activation receptors is typically associ-
ated with decreased NK cell activity and increased disease severity, it has recently been
reported to be an important mechanism for NK cell survival, motility, and serial engagement
of target cells [9]. In vitro models of NK cell responses to tumors have focused on the prototyp-
ical NK cell-sensitive leukemic cell line, K562 [10]. We have previously demonstrated that
another leukemic cell line, CTV-1, is capable of priming NK cells to display enhanced effector
functions [3]. Although both K562 and CTV-1 cells are sensitive to NK cell killing, CTV-1
cells are less susceptible and can “prime” NK cells for subsequent killing of targets [4]. In con-
trast, it has been reported that the encounter with K562 cells induces functional anergy in NK
cells and renders them less responsive to further stimulation [11–13].
We investigated the consequences of tumor cell- or cytokine-based priming on the pheno-
type, cytokine secretion profile, and transcriptome of NK cells to identify signatures that dif-
ferentiate these cell populations. In summary, priming human NK cells from healthy
individuals with tumor cells downregulates the expression of activation receptors, triggers the
Tumor-primed natural killer cell signature
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secretion of pro-inflammatory cytokines, and induces differential gene expression, which is
tumor cell-dependent and distinct to that induced by lymphokine activation. Understanding
tumor-specific NK cell responses is an important step toward maximizing the therapeutic
potential of NK cells in cancer treatment.
Materials and methods
Cells
Peripheral blood (PB) samples were obtained from healthy donors with prior informed consent.
Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation
from which NK cells were isolated using positive selection for CD56 (CD56 MicroBeads; Milte-
nyi Biotec) or negative selection using EasySep Human NK Cell Enrichment Kit (StemCell
Technologies). Both procedures were conducted according to the manufacturers’ protocols
with purity routinely>92% CD56+CD3-. Freshly-isolated NK cells were maintained in com-
plete growth medium (CM) (RPMI 1640 supplemented with 10% v/v fetal bovine serum and
2mM L-glutamine; all from Life Technologies). The K562 chronic myelogenous leukemia cell
line, CTV-1 acute lymphoblastic leukemia cell line, Daudi Burkitt lymphoma cell line, RPMI-
8226 myeloma cell line and MCF-7 breast cancer cell line (DSMZ) were maintained in CM. NK
cell stimulation was achieved by co-incubating CD56+CD3- NK cells (1x106) with untreated or
mitomycin-C-treated K562, CTV-1, Daudi, RPMI-8226 or MCF-7 cells (2x106), or the exoge-
nous cytokines IL-2 (200 IU/ml), IL-12 (20 ng/ml), IL-15 (10 ng/ml) or IL-18 (100 ng/ml)
(R&D Systems) alone or in combination as indicated, for 6 or 16 hours at 37˚C, 5% v/v CO2 in
CM. Obtaining blood from healthy donors was approved by the University College London-
Royal Free Hospital Biobank Ethical Review Committee (NC.2015.019).
Flow cytometry
The following fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from
BD Biosciences: CD56 (clone B159), CD3 (clone SK7), CD314 (NKG2D; clone 1D11), CD226
(DNAM-1; clone DX11), CD25 (clone M-A251), CD62L (clone DREG-56), CD69 (clone L78),
CD184 (CXCR4; clone 12G5), CD335 (NKp46; clone 9E2), and CD337 (NKp30; clone p30-
15). CD336 (Nkp44; clone 253415), STAT5A (clone 251610), VEGF (clone 23410), ULBP1
(clone 170818), ULBP3 (clone 166510), ULBP2/5/6 (clone 165903), and B7H6 (clone 875001)
mAbs were purchased from R&D Systems. NKp80 (clone 4A4.D10), CD16 (clone VEP3),
CD137 (4-1BB; clone 4b4-1), IFN-γ (clone 45–15), TNF-α (clone cA2), MIP-1α (CCL3; clone
REA257), MIP-1β (CCL4; clone REA511), MICA/B (clone 6D4), CD155 (clone PV404.19),
RANTES (CCL5; clone REA346), and CD244 (2B4; clone REA112) mAbs were purchased
from Miltenyi Biotech. CD11a (clone HI111), CD54 (clone RR1/1), and CD57 (clone TB01)
mAbs were purchased from eBiosciences. CD181 (CXCR1; clone 8F1/CXCR1), CXCR7 (clone
8F11-M16), CD112 (clone TX31) and HLA-A/B/C (clone W6/32) mAbs were purchased from
Biolegend. TNFAIP3 (A20; clone EPR2663), and MAP2K3 (clone EPR17345-104) mAbs were
purchased from Abcam.
To analyze cell surface antigen expression, cells (105 cells in 100 μl of Hank’s Balanced Salt
Solution, HBSS) were incubated with fluorochrome-conjugated mAbs at the manufacturer’s
recommended concentration for 15 minutes at room temperature. For intracellular staining,
after surface staining, cells were washed, fixed, permeabilized (Cytofix/Cytoperm; Becton
Dickinson), and stained with fluorochrome conjugated mAbs. Finally, cells were washed and
analyzed using flow cytometry (MACSQuant with MACSQuantify software; Miltenyi Biotec
or Novocyte with NovoExpress software; ACEA Biosciences). Brefeldin A (GolgiPlug; Becton
Dickinson) and Monensin (GolgiStop; Becton Dickinson) were added 5 hours before the end
Tumor-primed natural killer cell signature
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of the incubation period. The applicable isotype and fluorescence minus one (FMO) controls
were included in each experiment. A minimum of 20,000 CD56+CD3- events were acquired
after electronic gating on viable cells using forward (FSC) and side (SSC) scatter signals and
TO-PRO-3 iodide staining (Thermo Fisher Scientific).
Cytokine secretion measurements
Freshly-isolated resting NK cells (2×105) were washed twice and incubated alone or with
tumor cell lines (4×105), IL-2 (200 IU/ml), or IL-12 (20 ng/ml) in 200 μL of CM for the indi-
cated time at 37˚C in 5% v/v CO2. Thereafter, cell-free supernatants were collected and stored
at −80˚C pending analysis using a 25-plex immunoassay (Luminex 100 IS; Invitrogen). Values
from blank controls, or blank controls with target cells incubated alone as in the case of target-
stimulated NK cells, were subtracted from the data. To quantify human transforming growth
factor beta (TGF-β) secretion, supernatants were analyzed using a Quantikine enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems) according to the manufacturer’s instruc-
tions. Optical density values from standard controls were used to interpolate X values of secre-
tion measurements in pg/ml following baseline correction using blank controls.
RNA-sequencing
The transcriptome of NK cells after stimulation with tumor cells or cytokines was profiled by
RNA-sequencing (RNA-Seq). For this, resting NK cells (5×105) were washed twice and incu-
bated alone or with either mitomycin-C-treated K562 or CTV-1 cells (1x106) for 6 hours or
with IL-2 (200 IU/ml) for 16 hours at 37˚C in 5% v/v CO2, after which NK cells were isolated
from the co-culture using positive selection for CD56. RNA was extracted from the samples
using the RNAqueous Micro Kit (Thermo Fisher Scientific) and stored at −80˚C. To prepare
the library, 100 ng of total RNA was processed using the KAPA mRNA HyperPrep Kit (p/n
KK8580) according to the manufacturer’s instructions. Briefly, mRNA was isolated from total
RNA using Oligo dT beads to pull down poly-adenylated transcripts. The purified mRNA was
fragmented using chemical hydrolysis (heat and divalent metal cation) and primed with ran-
dom hexamers. Strand-specific, first strand cDNA was generated via a reverse transcriptase
procedure in the presence of Actinomycin D. This allows for RNA-dependent synthesis while
preventing spurious DNA-dependent synthesis. The second cDNA strand was synthesized
using dUTP in place of dTTP to mark the second strand. The resultant cDNA was then “A-
tailed” at the 3’ end to prevent self-ligation and adapter dimerization. Full-length xGen adap-
tors (IDT) containing two unique 8-bp sample-specific indexes, a unique molecular identifier
(N8), and a T overhang were ligated to the A-Tailed cDNA. Successfully ligated cDNA mole-
cules were then enriched with limited cycle PCR (14 cycles; the actual number is dependent on
the amount of input RNA). The high-fidelity polymerase employed in the PCR is unable to
extend through uracil. Thus, only first strand cDNA was amplified for sequencing, making the
library strand-specific (first-strand). Prior to sequencing, libraries to be multiplexed in the
same run were pooled in equimolar quantities, calculated from Qubit and Bioanalyser frag-
ment analysis. Samples were sequenced on the NextSeq 500 instrument (Illumina) using a 75
bp single read run with a corresponding 8 bp UMI read. For data analysis, run data were
demultiplexed and converted to fastq files using Illumina’s bcl2fastq Conversion Software
v2.19. Fastq files were then aligned to the human genome UCSC hg38 using RNA-STAR
2.5.2b then UMI deduplicated using Je-suite (1.2.1). Reads per transcript were counted using
FeatureCounts and differential expression was estimated using the BioConductor package
SARTools, which is a DESeq2 wrapper. All annotations and sequences were obtained from
Illumina iGenomes (http://emea.support.illumina.com/sequencing/sequencing_software/
Tumor-primed natural killer cell signature
PLOS ONE | https://doi.org/10.1371/journal.pone.0218674 June 26, 2019 4 / 20
igenome.html). Functional annotation analysis using gene ontology (GO) terms was per-
formed on gene data sets that met the cutoff values (>1 Log2fold change, P-value <0.05) using
the Panther Classification System gene list analysis tool (http://pantherdb.org)
NanoString nCounter gene expression assay
Additional gene expression profiling was conducted using a NanoString Technologies nCounter
FLEX amplification-free gene expression profiling platform. The nCounter system directly
detects and counts nucleic acids via reporter probes appended with multiple fluorophore bar-
codes and biotinylated capture probes that attach to microscopic beads. These are affixed to lanes
in a translucent cartridge and read in an optical scanner. To prepare the samples, resting NK cells
(5×105) were washed twice and incubated alone or with mitomycin-C-treated CTV-1 cells
(1×106) for 6 hours or with IL-2 (200 IU/ml) for 16 hours at 37˚C in 5% v/v CO2. Thereafter, NK
cells were selectively enriched from co-culturing by CD56 isolation, and RNA was extracted from
the samples using the RNAqueous Micro Kit (Thermo Fisher Scientific). Batches of 12 separate
samples at one time were prepared according to the manufacturer’s instructions and hybridized
with probes at 65˚C for 18 hours. They were then placed into the automated nCounter Prep Sta-
tion (NanoString Technologies) in which samples were affixed to cartridges. Cartridges were
immediately placed into the nCounter Digital Analyzer (NanoString Technologies) and read at
maximum resolution. Gene expression was directly measured through counts of corresponding
mRNA in each sample using nSolver software (NanoString Technologies). Following background
thresholding and normalization using the geometric mean of positive controls and housekeeping
genes, differential expression was calculated against NK alone control samples as a baseline.
Ingenuity pathway analysis
Functional analysis of gene expression changes was undertaken using Ingenuity Pathway
Analysis (IPA, Ingenuity Systems). This software analyzes RNA expression data in the context
of known biological responses, regulatory networks, and other higher-order response path-
ways. IPA identified canonical pathways, upstream regulators, signaling networks, biological
functions, and/or diseases that were most significant. Genes from the data set that met the cut-
off values (>1 Log2fold change, P-value <0.05) were considered for analysis. The Fisher’s
exact test was used for all analyses to calculate a P-value determining the probability that each
biological function assigned to the data set was due to chance alone. The overall activation/
inhibition states are predicted based on a Z-score algorithm, which is the negative log of the P-
value derived from the Fisher’s exact test.
Statistical analysis
Antigen expression and cytokine secretion profiles were analyzed with GraphPad software
(GraphPad Software). Statistical comparisons between normally distributed pairs of matched
samples (confirmed by the F test) were tested for significant differences in their means by the
paired t-test. Variables are presented as means ± standard deviation (SD) or as a percentage
change in mean relative to untreated samples (% change in mean ± SD of difference). P-values
<0.05 were considered statistically significant.
Results
Tumor-priming results in a loss of NK cell activation receptor expression
Loss of NK cell activation receptor expression is commonly reported in cancer [14–16]. We set
out to determine the antigen expression profiles of peripheral blood-derived NK cells from
Tumor-primed natural killer cell signature
PLOS ONE | https://doi.org/10.1371/journal.pone.0218674 June 26, 2019 5 / 20
healthy donors upon exposure to tumor targets or cytokines by incubating freshly-isolated
cells in medium alone, with K562, CTV-1, Daudi, RPMI-8226, or MCF-7 tumor cell lines, the
individual cytokines IL-2, IL-12, IL-15, or IL-18, or a combination of IL-12/15/18. Cells were
washed, and the expression of NK cell activation receptors was determined by flow cytometry
(Fig 1A). As expected, NK cells exhibited similar or higher expression of the senescence
marker CD57 and the activation marker NKp44 following stimulation with different tumor
cell lines or cytokines. In line with previous studies, co-incubation of NK cells with the leuke-
mic cell line K562 significantly reduced the number of NK cells expressing the Fc receptor
CD16 and the lymph node trafficking receptor CD62L compared to NK cells incubated in
medium alone (p< 0.01) [17]. NK cell stimulation using K562 also significantly decreased the
percentage of NK cells expressing the bone marrow trafficking receptor C-X-C chemokine
receptor (CXCR)-4; the co-stimulatory receptors intracellular adhesion molecule (ICAM)-1,
DNAM-1, 2B4 and NKG2D; and the NCRs NKp46 and NKp80 (p< 0.04).
K562 is sensitive to NK cells due to low to no expression of MHC class I molecules and the
expression of ligands for NK cell co-stimulatory receptors such as NKG2D, DNAM-1, NKp30,
CD2, and LFA-1 (S1 Table) (S1 Fig) [18]. CTV-1 leukemic cells also present co-stimulatory
ligands for NKG2D, DNAM-1, CD2, and LFA-1, but strongly express MHC class I molecules
[4]. Co-incubating NK cells with CTV-1 downregulated the expression of all activation recep-
tors aside from CD57 and NKp44, to the extent that there were significant reductions in the
proportions of NK cells expressing these receptors (p < 0.04). We further investigated the
effect of CTV-1 stimulation on NK cell activation receptor expression and observed an
increase in the percentage of cells expressing the activation markers CD25 (mean increase
28.1% ± 9.55; p = 0.003) and CD69 (mean increase 38.6% ± 14.8; p = 0.004), but no significant
change in the expression of other activation receptors, relative to unstimulated NK cells was
observed (Fig 1B).
NK cell stimulation with the insensitive lymphoma cell line Daudi induced a small but sig-
nificant reduction in the proportion of NK cells expressing 2B4, NKp46, and NKp80
(p< 0.03) but slightly increased the number of NK cells expressing NKp30 relative to NK cells
incubated in medium alone (Fig 1A). Daudi cells exhibit low to no MHC Class I expression
and express fewer ligands for the engagement of NK cell activation receptors such as NKG2D
and DNAM-1 relative to the leukemic cell lines K562 and CTV-1 (S1 Table). Co-incubating
NK cells with the MHC Class I positive, NK- sensitive myeloma cell line RPMI-8226 reduced
the percentage of CXCR4+ NK cells (mean decrease 50.65% ± 20.38; p = 0.005) without signifi-
cant change in the expression of other activation receptors compared to unstimulated NK cells
(Fig 1A). NK cell exposure to the MHC class I positive, NK-insensitive breast adenocarcinoma
cell line MCF-7 cells did not affect the expression of NK cell activation receptors relative to NK
cells incubated in medium alone. Since the presence of soluble factors such as TGF-β in the
tumor microenvironment (TME) can significantly affect NK cell phenotype and function in
response to target cell stimulation, we analyzed TGF-β1 content in the supernatant of tumor
target cells incubated alone or co-cultured with NK cells but found no detectable levels of
TGF-β1 secretion (S2 Fig) [19, 20].
Exposure to IL-2, IL-12, IL-15, or IL-12/15/18 induced a similar “trafficking” signature to
that induced by tumor cells: CXCR4 and CD62L expression was downregulated compared to
unstimulated NK cells. Exposure to IL-2 slightly increased the percentage of NK cells express-
ing 2B4 compared to unstimulated NK cells (p = 0.03). Although IL-18 did not significantly
affect NK cell receptor expression when used alone, exposure to IL-12/15/18 increased the per-
centage of NK cells expressing NKp30 (mean increase 31.05% ± 14.43; p = 0.009) compared to
NK cells incubated in medium alone. Thus, priming with different target tumor cells and cyto-
kines induces distinct and differential NK cell antigen expression profiles.
Tumor-primed natural killer cell signature
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Tumor-priming promotes the rapid secretion of pro-inflammatory
cytokines by NK cells
We investigated the influence of target cell recognition on the release of soluble mediators by
NK cells. Previous studies have defined the cytokine profile of NK cells following target cell
Fig 1. Loss of NK cell activation receptor expression following tumor-priming. (A) Freshly isolated NK cells were
incubated in medium alone, with K562, CTV-1, Daudi, RPMI-8226, or MCF-7 cells or with IL-2/12/15/18 (individually
or in combination) overnight at 37˚C. Thereafter, cells were washed. NK cell activation receptor expression was analyzed
using flow cytometry. The percentage change of NK cell expression was calculated for each receptor after stimulation
and results are presented as the mean of 3–5 different donors. Red indicates an increase, and green indicates a decrease
in receptor expression, according to the key on the right, relative to NK cells in medium alone. (B) Freshly isolated NK
cells were incubated in medium alone or with CTV-1 cells overnight at 37˚C. Cells were washed, the surface expression
of 20 different NK cell activation receptors was analyzed. Bars represent the means ± SD of 5 different donors. The
percentages of NK cell expression of different receptors after stimulation was compared with those in cells treated with
medium alone using the paired t-test. Statistical significance is indicated as: �P<0.05; ��P<0.01; ���P<0.001.
https://doi.org/10.1371/journal.pone.0218674.g001
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stimulation with K562 [10]. Although CTV-1 cells induced an NK cell antigen expression pro-
file that was similar to that induced by K562 cells, we have previously shown that CTV-1 prim-
ing enhances the cytolytic function of NK cells in vitro, whereas K562-mediated priming has
no effect on cells’ cytolytic capacity [4]. We analyzed cytokine release by NK cells following
their exposure to CTV-1 cells. Resting NK cells were co-incubated in medium alone or with
CTV-1 cells for 6 h. Supernatants were harvested, and the concentration of 25 different soluble
factors was determined by a multiplex immunoassay (Fig 2A). Low to moderate levels of the
chemokines MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), and IL-8 (CXCL8) and the
cytokines IL-1Rα, IL-1β, and IL-6 were detected in supernatants from NK cells incubated
without target cells, with CTV-1 stimulation inducing a 107-, 124-, 22-, 3-, 7-, 7-, and 2-fold
increase in their secretion, respectively. CTV-1 stimulation of NK cells also induced the secre-
tion of low to moderate levels of IFN-γ (p = 0.02), TNF-α (p = 0.03), IL-2Rα, IFN-γ-inducible
protein (IP)-10 (or CXCL10), and IL-12p40/p70. In contrast to previous studies using cyto-
kine-cultured NK cells [21, 22], incubation with CTV-1 cells had minimal or no effect on the
secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-5, and IL-13. In
contrast to previous studies using K562-stimulated NK cells [10], CTV-1 stimulation of NK
cells did not induce the secretion of detectable levels of monocyte chemoattractant protein
(MCP)-1 (or CCL2), monokine induced by gamma-interferon (MIG) (or CXCL9), IL-7, or
IFN-α. IL-2, IL-4, IL-5, IL-13, IL-15, IL-17, and eotaxin (CCL26) secretion by NK cells was not
detected. Similar to previous studies on target cell recognition of K562 by NK cells [10], incu-
bating NK cells with CTV-1 cells for 6 hours induced greater cytokine secretion by NK cells
(Fig 2B).
We next compared the secretion of soluble factors after stimulation of NK cells with differ-
ent target cells and cytokines. For these studies, resting NK cells were incubated in medium
alone, co-incubated with CTV-1 or K562 cells for 6 h or with IL-2 or IL-12 overnight. Superna-
tants were harvested, and the concentrations of IFN-γ, TNF-α, MIP-1α, MIP-1β, RANTES,
IL-R2α, IL-1α, and IL-1β determined by a multiplex immunoassay (Fig 3). Levels of soluble
factors in the supernatants from CTV-1 and K562 cells that had been incubated alone were
subtracted from those that were present in co-cultured NK cells. Interestingly, incubating NK
cells with CTV-1 cells induced a consistently greater secretion of IFN-γ, TNF-α, MIP-1α,
RANTES, IL-2Rα, and IL-1β than that induced by co-incubation with K562 cells. Cytokine-
priming NK cells with IL-2 or IL-12 induced similar or higher levels of cytokine secretion by
NK cells compared to co-incubation with CTV-1 cells. Since NK cells can induce the secretion
of soluble factors in target cells, we confirmed TpNK cell secretion of cytokines such as IFN-γ,
TNF-α, MIP-1α, MIP-1β, and RANTES using flow cytometry, which is consistent with previ-
ous studies using CTV-1 and K562 (S3 Fig) [4, 10].
Tumor-priming induces a specific transcriptional signature in NK cells
NK cell activation is associated with simultaneous changes in the expression of multiple genes
[6]. We studied the influence of exposure to tumor targets or cytokines on the NK cell tran-
scriptome. For this, resting NK cells were incubated in medium alone, with mitomycin C–
treated K562 or CTV-1 cells for 6 hours, or with IL-2 overnight, after which RNA was
extracted from NK cells that had been isolated from the co-culture. Gene expression was ana-
lyzed using RNA-Seq or the NanoString nCounter FLEX amplification-free gene expression
profiling platform (Fig 4A). RNA-Seq analysis revealed that stimulation with K562, CTV-1, or
IL-2 induced the expression of a number of common genes by NK cells (e.g., SOCS1/2,
ULBP1/2, SIGLEC12, E2F1/2, BCL21, CDCA5, WEE1, EGR1, HMGB3), compared to NK cells
incubated in medium alone (S2 Table). Following stimulation, the most upregulated gene was
Tumor-primed natural killer cell signature
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HSPA1A—the intracellular expression of which is linked to the promotion of protein
chaperoning, transport, and folding of naïve and mutated proteins and cytoprotection in the
presence of stress or activation stimuli (S3–S5 Tables) [23]. Functional analysis using available
GO annotations in public databases suggests that the observed overlap in gene expression is
reflective of common cellular and metabolic processes after target cell or cytokine stimulation
(S4 Fig).
A specific tumor-induced gene expression signature was observed in NK cells after expo-
sure to K562 or CTV-1 targets. The gene expression profile of NK cells in which cytotoxicity
has been fully triggered through exposure to NK-sensitive K562 cells exhibits the overexpres-
sion of many genes relative to resting NK cells or NK cells that have been primed for subse-
quent killing by co-incubation with the less sensitive target cell line CTV-1 or IL-2 (Fig 4B).
Incubation with K562 cells also exclusively induced the downregulation of numerous genes
Fig 2. Influence of CTV-1 cell priming on pro-inflammatory cytokine secretion by NK cells. (A) Freshly isolated
NK cells were incubated alone or with CTV-1 cells for 6 hours at 37˚C. Supernatants were harvested, and the
concentrations of 25 different cytokines and chemokines were determined using a multiplex immunoassay. Bars
represent means ± SD of 4 different donors. Post-stimulation cytokine secretion by NK cells was compared with that of
cells incubated in medium alone using the paired t-test. Statistical significance is indicated as: �P<0.05; ��P<0.01;
���P<0.001. (B) NK cells were incubated with CTV-1 cells at 37˚C. Supernatants were harvested at different time
points, as indicated, and the concentrations of IFN-γ, TNF-α, MIP-1α, MIP-1β, and RANTES were determined by a
multiplex immunoassay. Values represent mean ± SD of 4 different donors.
https://doi.org/10.1371/journal.pone.0218674.g002
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Fig 3. Influence of tumor- or cytokine-priming on cytokine secretion by NK cells. NK cells were incubated in
medium alone, with K562, or CTV-1 cells for 6 hours or with IL-2 or IL-12 overnight at 37˚C. Supernatants were
harvested, and the concentrations of IFN-γ, TNF-α, MIP-1α, MIP-1β, RANTES, IL-R2α, IL-1α, and IL-1β were
determined by a multiplex immunoassay. Bars represent means ± SD of 4 different donors. Post-stimulation NK cell
cytokine secretion was compared with that in cells incubated in medium alone using the paired t-test. Statistical
significance is indicated as: �P<0.05; ��P<0.01; ���P<0.001.
https://doi.org/10.1371/journal.pone.0218674.g003
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including GZMA/B, HAVCR1/2, JAK1/3, MAP3K2/3/5/9/10/12/13 relative to unstimulated
NK cells, which may explain previous reports on NK cell functional inactivation after K562
stimulation [11–13]. CTV-1 stimulation of NK cells affected many genes common to K562
stimulation including the upregulation of CCNB1/2, VGF, STAT5A, MARCKSL1, ICAM5, and
FUT3 relative to NK cells incubated alone (S6 Table). The influence of NK-target cell interac-
tions induced the largest overlap in the transcriptome of NK cell across all conditions with 544
common genes exclusively affected by K562 or CTV-1 stimulation but not IL-2 (Fig 4C and
4D). The Ingenuity pathway analysis also revealed an overlap in specific biological functions,
Fig 4. Differential influence of tumor cell or cytokine priming on the transcriptome of NK cells. (A) Schematic of the workflow in obtaining NK cell gene expression
profiles after tumor cell or cytokine priming. Human NK cells were isolated from peripheral blood and incubated in medium alone, mitomycin-C-treated K562, or
CTV-1 for 6 h or with IL-2 overnight. NK cells were enriched from co-cultures, and RNA extraction and gene expression profiling were performed using RNA-Seq or
the NanoString nCounter FLEX platform. (B) Hierarchical clustering was applied to the gene expression values, and the top differentially expressed genes are shown in a
heat map with rows representing the relative expression of each gene across 12 samples. Red corresponds to higher gene expression, and blue corresponds to lower gene
expression. Similarity in gene expression patterns between different samples are reflected in the resulting dendrogram. Z-Score is calculated using the following formula:
(gene expression value in sample of interest)—(mean expression across all samples) / SD. Venn diagrams generated by the intersection of list of genes upregulated (C) or
downregulated (D) by at least 1 Log2fold (P<0.05) vs. NK cells incubated in medium alone are shown.
https://doi.org/10.1371/journal.pone.0218674.g004
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canonical pathways, and upstream regulators associated with the transcriptional responses of
NK cells activated through target cell recognition (S5 Fig).
To further investigate NK cell transcriptional responses associated with enhanced subse-
quent killing of tumor targets, NK cell gene expression profiles were analyzed using Nano-
String nCounter FLEX amplification-free gene expression profiling platform after NK cell
incubation in medium alone, with CTV-1 cells, or with IL-2. Consistent with the RNA-Seq
results, the gene expression profiles of NK cells after exposure to CTV-1 or IL-2 partially over-
lapped with the upregulation of genes involved in enhanced effector functions such as cytotox-
icity (e.g., FAS, TNSF10, CD69, CD80, CD83, and MAPK11) and cytokine secretion (e.g., TNF,
IFNG, CCL3/4/8, and CXCL9/11) (S7 Table). However, tumor-priming with CTV-1 cells pref-
erentially induced overexpression of genes including CCNB2, DUSP2, MAP2K3, MARCKSL1,
STAT5A, and TNFAIP3. Table 1 lists the genes for which the expression is influenced by incu-
bation with CTV-1 cells or IL-2 and the biological functions associated with their expression.
The majority of genes preferentially overexpressed in LAK cells (including IL-6, CCL1/20/22,
CCR7, and CXCL1/2/3/5/8) are associated with cytokine/chemokine molecules involved in
cell-to-cell signaling. These findings align with previous studies reporting on the IL-2 activa-
tion of NK cells [24]. In contrast, the top biological functions associated with the expression of
genes that are exclusively influenced by tumor-priming relate to cell death and survival. The
top signaling network associated with the transcriptome of tumor-primed NK cells is shown
in Fig 5 and demonstrates the central role of genes exclusively affected by CTV-1 stimulation
in the tumor-priming pathway. Although gene expression data show differences in NK cell
responses to tumor-priming, post-transcriptional mechanisms can highly impact the protein
repertoire of cells. Crucial molecules exclusively upregulated by TpNK cells like CD70 and
CD137 (TNFRSF9 or 4-1BB) were analyzed using flow cytometry to demonstrate NK cell
upregulation of expression following target cell recognition (S6 Fig). However, other signaling
Table 1. NK cell gene expression exclusively affected by CTV1- or IL-2-priming.
NK cell
stimulus
Genes affected (vs medium) Top biological functions
CTV-1 Upregulated: BIRC5, CCNB2, CD70, CXCL10,
DUSP2, DUSP6, EEF1A1, EGR2, EGR3, FGFR1,
FLT1, GPR183, HIST2H2AA3, IL4I1, INSIG1,
MAP2K3, MARCKSL1, NDC80, NR4A2, RHOC,
RHOG, SERPINE1, STAT5A, TNFAIP3, TNFSF9,
TOP2A, TTK and VEGFA. Downregulated: CCR1,
FCGR2A, NCF2, RAB3D, SERPINB2 and THB.
Cell death and survival, cellular function and
maintenance, cellular movement, cellular
development, cellular growth and proliferation
IL-2 Upregulated: ACTB, ADAMTS1, ADORA2A,
AGK, ARF6, BATF, CALR, CASP7, CCL1, CCL20,
CCL22, CCR7, CD274, CD38, CD40, CD40LG,
CEBPB, CEBPG, CSF1, CXCL1, CXCL2, CXCL3,
CXCL5, CXCL8, CYTIP, DPP4, ELOVL6, FURIN,
G6PD, GCH1, GZMA, HAVCR1, HIF1A, ID2,
IL27RA, IL3RA, IL6, IRF, ISG15, ITGB7, JAK3,
LAG3, LAMP3, LDLR, LTB, MAFF, MSC, MX1,
MX2, PDE4A, PSMB9, PSME2, PTGER2, RIPK2,
SERPINB2, STAT1, STAT3, TAP1, TAP2, TAPBP,
TNFRSF1B, TNFSF4, TRAF2, TRAFD1, TREX1
and VASP. Downregulated: AIF1, AOAH, C3AR1,
CD27, CD84, CEBPA, CLEC7A, CXCR2, CXCR4,
FCGR2B, HDAC5, HLA-DMA, JAML, LAPTM5,
MRC1, OLR1, PTGDR, RASAL1, S1PR1,
SMARCD3, SPTBN1, TLR1 and TYROBP.
Cell-to-cell signaling and interaction, cellular
movement, cellular function and maintenance,
cellular growth and proliferation, cellular
development
https://doi.org/10.1371/journal.pone.0218674.t001
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molecules such as MAP2K3, STAT5a, TNFAIP3, and VEGF showed no difference in protein
expression between resting and primed NK cells. The relationship between mRNA and protein
levels can vary depending on the dynamic state of the cells, and other factors like protein half-
life and post-translational mechanisms can play a role in the observed differences between
mRNA and protein levels [25]. Thus, in many cases, a delay between observed differences in
transcriptional induction and protein levels should be considered. Future functional studies of
key genes regulating TpNK signaling pathways identified in this paper may identify new bio-
markers or reveal previously unknown drivers of NK cell anti-tumor function.
Discussion
NK cell recognition of tumor targets can involve a wide array of cell surface receptors, which
trigger downstream signal transduction pathways that are ultimately integrated to determine
activity [2]. The ability of NK cells to mediate cytotoxicity against tumor cells co-evolved
alongside tumor escape mechanisms that facilitate tumorigenesis without triggering the signal-
ing threshold for full NK cell activation. Tumor resistance can be overcome by priming NK
cells in vitro via two mechanisms: cytokine stimulation and target cell recognition [26]. In this
study, we report loss of activation receptor expression, rapid pro-inflammatory cytokine
Fig 5. Top cell signaling network induced in tumor-primed NK (TpNK) cells as generated by Ingenuity pathway analysis. Nodes represent genes that are either
upregulated (red), downregulated (green), or absent from our original differential expression analysis (white), but play an important role in the tumor-specific signaling
network according to Ingenuity Pathway Analysis. The intensity of node color signifies the extent of change in expression of the respective gene relative to NK cells
incubated in medium alone. Node shapes and the relationships between different genes are outlined in the figure legend.
https://doi.org/10.1371/journal.pone.0218674.g005
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secretion, and tumor-specific gene expression signature induction in NK cells following prim-
ing with tumor targets, which is independent of cytokine stimulation.
NK cells isolated from patients with cancer commonly display low levels of activation
receptors, which has been associated with NK cell dysfunction [15, 27–30]. Exposing NK cells
to targets has been shown to downregulate the expression of several activation receptors,
including NKG2D, CD16, NKp30 and NKp46. NKG2D downregulation occurs as a conse-
quence of its engagement by membrane-bound or soluble ligands to induce clatherin-medi-
ated endocytosis and activation of the ERK1/2 signaling pathway via the DAP10 signaling
adaptor [31, 32]. Exposure to TGF-β is also one of the main mechanisms through which sur-
face expression of NKG2D and NKp30 is downregulated [33, 34]. Other receptors, such as
CD16, are downregulated via proteolytic cleavage by A disintegrin and metalloproteinase
(ADAM)-17 or matrix metalloproteinase (MMP)-25; we have previously hypothesized that
this mechanism enables dimerized CD3-z to associate with CD2 in order to provide essential
co-stimulation, as first reported by Warren et al. over 20 years go [4, 17, 35, 36]. Although the
downregulation of activation receptors has been proposed as a regulatory mechanism to
dampen NK cell activity, our group and others have previously reported that this NK cell phe-
notype is associated with enhanced NK cell cytotoxicity against tumor targets [3, 4, 17, 37–39].
We have also shown that tumor-priming NK cells induces the expression of NK cell activation
markers such as CD69 and CD25; the secretion of pro-inflammatory cytokines, including
MIP-1 α /β, RANTES, IL-6, IL-8, and IL-1β; and upregulation of numerous genes that are
associated with enhanced NK cell cytotoxicity and immunomodulatory functions (including
FAS, TNFSF10, CD80, MAPK11, TNF, IFNG, CCL3/4/8, and CXCL9/11).
It is possible that NK cells involved in tumor recognition downregulate surface receptors as
part of the priming process and that the internalization or cleavage of these from the cell sur-
face is essential for optimal NK cell function. Through the use of pharmacological inhibitors
and NK cells transfected to express a non-cleavable form of CD16, receptor shedding was
recently shown to positively regulate NK cell activity by enhancing survival, motility, and serial
engagement of target cells [9]. Although the downregulation of CD16 expression renders NK
cells less sensitive to subsequent activation via that receptor, they remain responsive to further
stimulation via other receptors. This can explain the responsiveness of NK cells previously
primed with CTV-1 to subsequent stimulation with other target cells. Other metalloprotei-
nases, such as ADAM9, were upregulated after tumor recognition and may play a similar role
in downregulating the expression of other NK cell receptors, such as NKG2D or NKp46 and
promoting NK cell survival and serial engagement with targets [40]. These findings may
explain why therapeutic interventions to prevent receptor downregulation through ADAM17
inhibitors have not proved successful thus far. Downregulation of NK cell surface receptors
like the bone marrow trafficking receptor CXCR4 after cytokine-priming, can also be strength-
ened or reversed by other soluble factors in the microenvironment [19]. This might explain
why IL-18 had a synergistic effect on CXCR4 downregulation when used with IL-12 and IL-
15, relative to NK cell exposure to any of the cytokines alone.
Administering CTV-1-primed NK cells to patients with acute myeloid leukemia has been
shown to be more clinically effective than IL-2 activated NK cells [41, 42]. Insight into the
mechanism(s) underlying these different clinical responses is provided by the differential tran-
scriptional activity in NK cells, which is triggered by co-incubation with CTV-1 cells or IL-2
stimulation. Consistent with previous studies, the majority of genes that are preferentially
overexpressed after exposure to IL-2 are involved in cell-to-cell signaling, whereas CTV-1
stimulation upregulated the expression of genes that are specifically associated with NK cell
cytotoxicity against tumor targets (including STAT5A, MAP2K3, DUSP2/6) [24]. For example,
the JAK-STAT signaling pathway, which is activated by both classes of stimuli, triggers
Tumor-primed natural killer cell signature
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STAT5A in TpNK cells, which plays a specific role in regulating immune responses to hypoxic
stress in the TME via the prolyl-4-hydroxylase domain enzyme (PHD)-3 and hypoxia-induc-
ible factors (HIF) [43]. Other stress signals associated with cancer progression lead to the acti-
vation of the MAPK pathway, which plays a critical role in NK cell lysis of tumor cells by
mobilizing granule components upon contact with NK cell-sensitive target cells [44]. This cru-
cial pathway is tightly regulated by several factors, including DUSP2/6 [45]. Pal et al. recently
reported enhanced tumor-specific NK cell cytotoxicity after tumor-priming with leukemic
patient specimens, which is linked to differences in gene expression compared to cytokine-
priming as well as the induction of memory-like function [46]. We identified other genes in
the transcriptome of tumor-primed NK cells that are likely to play a role in NK cell anti-tumor
responses that should be further investigated.
Previous studies characterizing tumor-associated NK cell responses using NK cells isolated
from patients with cancer and expanded ex vivo using IL-2 and an irradiated EBV-transformed
lymphoblastoid cell line demonstrated the overexpression of genes such as CCNB2, CCL4,
MIF, and TUBB, which were shown here to be upregulated after exposure to tumor targets
[47]. Moreover, these overexpressed genes were exclusively activated by IL-2 (e.g., CXCL5,
GZMA, and LTB). It is possible that NK cells activated by simultaneous or sequential exposure
to cytokines and target cells exhibit gene expression signatures that are an amalgam of the pro-
files observed in this study. Thus, our in vitro observations of changes in gene or receptor
expression in response to the independent effects of different tumor cells or cytokines may not
be recapitulated in the TME in vivo in which both classes of stimuli are present. Nonetheless,
characterizing the NK cell activation phenotype after exposure to tumor targets, which is dis-
tinct to and independent of cytokine stimulation, is an important step towards delineating the
specificity of NK cell anti-tumor responses.
NK cells are fast-acting lymphocytes, which is partially explained by high level of transcrip-
tional activity in their resting state [48]. Upon NK cell stimulation, protein levels can drasti-
cally increase without substantial changes to their respective mRNA levels. Thus, it is possible
that priming resting NK cells enhances NK cell function by promoting the translation of read-
ily abundant mRNA transcripts. In this study, the transcriptional activity for some genes that
are central to anti-tumor effector responses, such as GZMA, was not influenced after target cell
stimulation. A possible explanation may be that these genes are constitutively highly expressed
in resting NK cells and that target stimulation increases translation rather than transcription.
Differential NK cell phenotypic and transcriptional signatures that are induced after expo-
sure to tumor cells or cytokines highlight the complex nature of NK cell signaling and the
importance of both the target cell and cytokine milieu. Study limitations dictate that, until our
findings are replicated with more donors using different tumor targets and cytokine ratios and
concentrations indicative of the in vivo setting, speculation about in vivo implications of NK
cell responses remains premature. Previous reports of impaired NK cell function in patients
with cancer may be partly influenced by chronic exposure of peripheral blood NK cells to
tumor cells, thereby leading to a downregulation of activating ligands. Maintenance of patient-
derived NK cells in IL-2, which is a common laboratory practice, is likely to influence the phe-
notype and transcriptome of NK cells and explain the disparities in the published literature.
Future studies should aim to further contribute to our understanding of tumor-specific NK
cell responses by characterizing the expression of inhibitory receptors involved in immune
checkpoints and the priming responses of different NK cell subpopulations involved in tumor
recognition. Increasing evidence for a specific tumor-induced signature in NK cell responses
may have important implications in the clinic and key signaling molecules identified to play a
specific role in tumor target recognition by NK cells can be targeted to deliver effective thera-
peutic approaches for the treatment of cancer.
Tumor-primed natural killer cell signature
PLOS ONE | https://doi.org/10.1371/journal.pone.0218674 June 26, 2019 15 / 20
Supporting information
S1 Fig. Expression of NK cell ligands on different tumor cell lines. Tumor cell lines K562,
CTV-1, Daudi, RPMI-8226 and MCF-7 incubated alone at 37˚C in 5% v/v CO were assessed
for their expression of different NK cell ligands using flow cytometry. The experiment was per-
formed three times and representative plots are shown with light grey histograms representing
FMO controls and dark grey histograms representing stained samples.
(TIF)
S2 Fig. Analysis of human TGF-β1 secretion by tumor cells and NK cells. Tumor cell lines
K562, CTV-1, Daudi, RPMI-8226, and MCF-7 were incubated alone or with freshly-isolated,
resting NK cells for 16 hours at 37˚C in 5% v/v CO2. Thereafter, cell-free supernatants were
collected and stored at −80˚C pending analysis using a Quantikine ELISA kit according to
manufacturer’s instructions. Optical density values from standard controls were used to inter-
polate X values of secretion measurements in pg/ml following baseline correction using blank
controls. Tumor cell lines cultured alone or with NK cells did not secrete detectable levels of
TGF-β1.
(TIF)
S3 Fig. Intracellular staining of NK cell cytokine secretion following tumor-priming.
Freshly isolated NK cells were incubated in medium alone or with CTV-1 cells for 6 hours at
37˚C. Then, cells were surface-stained with fluorochrome-conjugated anti-CD56 and anti-
CD3 mAbs. Cells were fixed, permeabilized, and intracellularly stained with fluorochrome-
conjugated mAbs against IFN-γ, TNF-α, MIP-1α, MIP-1β, and RANTES. Brefeldin A and/or
monensin were added when appropriate 1 hour after incubation. Appropriate isotype and
FMO controls were included in each experiment. (A) Bars represent mean percentage NK cell
expression ± SD of 3–7 different donors. (B) Bars represent mean NK cell median fluorescence
intensity values ± SD of 3 different donors. NK cell expression after stimulation was compared
with cells treated with medium alone using the paired t-test. Statistical significance is indicated
as: �P <0.05; ��P<0.01; ���P<0.001.
(TIF)
S4 Fig. Functional analysis of NK cell gene expression overlap after stimulation with K562,
CTV-1 or IL-2 using the Panther classification system. Freshly isolated NK cells were incu-
bated in medium alone, with mitomycin-C- treated K562 or CTV-1 cells for 6 hours, or with
IL-2 overnight. Then, NK cells were selectively enriched from the co-culture, mRNA was
extracted, and gene expression was analyzed using RNA-sequencing. Functional annotation
analysis using gene ontology terms was performed on genes commonly upregulated after
exposure to K562, CTV-1, or IL-2 relative to NK cells incubated in medium alone that met the
cutoff values (>1 Log2fold change, P-value <0.05) using the Panther Classification System
gene list analysis tool.
(TIF)
S5 Fig. Ingenuity pathway analysis heatmaps of top biological functions, canonical path-
ways, and upstream regulators associated with NK cell gene expression profiles after stim-
ulation with K562, CTV-1, or IL-2. Freshly isolated NK cells were incubated in medium
alone, with mitomycin-C-treated K562 or CTV-1 cells for 6 hours, or with IL-2 overnight.
Then, NK cells were selectively enriched from the co-culture, mRNA was extracted, and gene
expression was analyzed using RNA-sequencing. Biological functions, canonical pathways,
and upstream regulators associated with NK cell genes variably expressed after exposure to
K562, CTV-1, or IL-2 relative to NK cells incubated in medium alone that met the cutoff values
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(>1 Log2fold change, P-value <0.05) were analyzed using Ingenuity pathway analysis soft-
ware. Colors indicate predicted activity according to activation z-scores, with orange predict-
ing an overall increase and blue indicating a decrease in activity relative to NK cells incubated
in medium alone.
(TIF)
S6 Fig. NK cell expression of tumor-associated signaling molecules following co-incuba-
tion with K562, CTV-1, or IL-2. Freshly isolated NK cells were incubated in medium alone or
with K562 or CTV-1 cells for 6 hours or IL-2 overnight at 37˚C. Then, cells were surface
stained with fluorochrome-conjugated anti-CD56, anti-CD3, anti-CD137, and anti-CD70
mAbs. Cells were fixed, permeabilized, and intracellularly stained with fluorochrome-conju-
gated mAbs against STAT5a, MAP2K3, TNFAIP3, and VEGF. Brefeldin A and/or monensin
were added when appropriate 5 hours before the end of the incubation period. Appropriate
isotype and FMO controls were included in each experiment. (A) Bars represent mean per-
centage NK cell expression ± SD of 3–5 different donors. (B) Bars represent mean NK cell
median fluorescence intensity values ± SD of 3–5 different donors.
(TIF)
S1 Table. Expression of ligands for NK cell receptors on different tumor cell lines.
(DOCX)
S2 Table. Overlap in NK cell gene expression from RNA-sequencing analysis after stimula-
tion with K562, CTV-1, or IL-2.
(DOCX)
S3 Table. Top 50 variably expressed NK cells genes according to log2fold change from
RNA-sequencing analysis after NK cell exposure to K562 cells.
(DOCX)
S4 Table. Top 50 variably expressed NK cells genes according to log2fold change from
RNA-sequencing analysis after NK cell exposure to CTV-1 cells.
(DOCX)
S5 Table. Top 50 variably expressed NK cells genes according to log2Fold change from
RNA-sequencing analysis after NK cell exposure to IL-2.
(DOCX)
S6 Table. Tumour-induced changes from RNA-sequencing analysis in NK cell gene expres-
sion after NK cell exposure to K562 or CTV-1.
(DOCX)
S7 Table. Overlap in NK cell gene expression from NanoString nCounter gene expression
profiling after stimulation with CTV-1 or IL-2.
(DOCX)
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